Skip to search formSkip to main contentSkip to account menu

SM 164

Known as: SM-164, SM164 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Bridged Bicyclo Compounds, HeterocyclicTriazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
SMAC mimetic SM-164 enhanced adriamycin induced apoptosis and cell cycle arrest in osteosarcoma cell line HOS
Osteosarcoma is the most common form of primary bone cancer in adolescent with a male predominance. Current treatment for… 
2016
2016
IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα
Outcomes for patients diagnosed with the bone cancer osteosarcoma have not improved significantly in the last four decades. Only… 
2015
2015
Effects of Physiological and Synthetic IAP Antagonism on c-IAP-Dependent Signaling
Cellular inhibitor of apoptosis proteins 1 and 2 (c-IAP1/2) have central roles in signal transduction mediated by numerous… 
2012
2012
Smac-mimetic compound SM-164 induces radiosensitization in breast cancer cells through activation of caspases and induction of apoptosis
Radiotherapy is a treatment choice for local control of breast cancer, particularly after the removal of tumor tissues by surgery… 
2012
2012
Smac Mimetic SM-164 Potentiates APO2L/TRAIL- and Doxorubicin-Mediated Anticancer Activity in Human Hepatocellular Carcinoma Cells
Background The members of inhibitor of apoptosis proteins (IAPs) family are key negative regulators of apoptosis. Overexpression… 
2012
2012
LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling.
Smac mimetics block inhibitor of apoptosis proteins to trigger TNFα-dependent apoptosis in cancer cells. However, only a small… 
Highly Cited
2011
Highly Cited
2011
Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment
Smac mimetics are being developed as a new class of anticancer therapies. Because the single-agent activity of Smac mimetics is… 
2010
2010
Efficacy of MDM2 inhibitor MI-219 against lung cancer cells alone or in combination with MDM2 knockdown, a XIAP inhibitor or etoposide.
The p53 tumor suppressor is negatively regulated by murine double minute 2 (MDM2), which binds to p53 and promotes p53… 
Highly Cited
2008
Highly Cited
2008
SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP.
Small-molecule Smac mimetics are being developed as a novel class of anticancer drugs. Recent studies have shown that Smac… 
Highly Cited
2007
Highly Cited
2007
Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP.
XIAP is a central apoptosis regulator that inhibits apoptosis by binding to and inhibiting the effectors caspase-3/-7 and an… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)